Literature DB >> 1233246

Renal function and the rate of disappearance of methotrexate from serum.

L O Kristensen, K Weismann, L Hutters.   

Abstract

The disappearance of methotrexate (MTX) from serum was studied using H3-MTX. The overall elimination half-life (MTX T1/2) was well defined from one to about six hours after i.v. administration; in 25 patients it ranged from 102 min to 750 min and was inversely related to endogenous creatinine clearance, which ranged from 6 to 140 ml/min. The corresponding apparent volume of distribution, V, obtained by extrapolation tended to decrease at lower levels of renal function. The total clearance of MTX calculated in this period varied linearly with creatinine clearance. In patients with normal serum creatinine concentration, the half-life increased with advancing age, which reflects the concurrent age-dependent decrease in creatinine production and renal function. This illustrates the need for knowledge of renal function, not based solely on serum creatinine concentration, in patients treated with methotrexate or other drugs eliminated by the kidneys. In 9 patients the results were not affected by treatment with diuretics (furosemide, hydroflumethiazide). In four patients serum MTX concentration was measured for up to 24-72 hours. An increasing half-life of MTX with time was found, suggesting that the elimination kinetics of the drug would be most adequately described by a multi-compartment model.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1233246     DOI: 10.1007/bf00562319

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  17 in total

1.  Physiological basis for the action of newer diuretic agents.

Authors:  K H BEYER; J E BAER
Journal:  Pharmacol Rev       Date:  1961-12       Impact factor: 25.468

2.  The fluorometric measurement of the absorption, distribution and excretion of single doses of 4-amino-10-methyl pteroylglutamic acid (amethopterin) in man.

Authors:  M V FREEMAN
Journal:  J Pharmacol Exp Ther       Date:  1958-01       Impact factor: 4.030

3.  Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid.

Authors:  S FARBER; L K DIAMOND
Journal:  N Engl J Med       Date:  1948-06-03       Impact factor: 91.245

4.  The metabolic fate of tritiated methotrexate. II. Absorption and excretion in man.

Authors:  E S Henderson; R H Adamson; V T Oliverio
Journal:  Cancer Res       Date:  1965-08       Impact factor: 12.701

5.  Pharmacokinetics of methotrexate.

Authors:  D H Huffman; S H Wan; D L Azarnoff; B Hogstraten
Journal:  Clin Pharmacol Ther       Date:  1973 Jul-Aug       Impact factor: 6.875

6.  Psoriasis-liver-methotrexate interactions.

Authors: 
Journal:  Arch Dermatol       Date:  1973-07

7.  Blood levels of methotreate and the treatment of psoriasis.

Authors:  K M Halprin; K Fukui; A Okawara
Journal:  Arch Dermatol       Date:  1971-03

8.  The effect of organic acids on renal clearance of methotrexate in man.

Authors:  D G Liegler; E S Henderson; M A Hahn; V T Oliverio
Journal:  Clin Pharmacol Ther       Date:  1969 Nov-Dec       Impact factor: 6.875

9.  [Psoriasis-cytostatic treatment with amethopterin (methotrexate)].

Authors:  G Rassner
Journal:  Fortschr Med       Date:  1973-03-22

10.  Liver damage due to methotrexate in patients with psoriasis.

Authors:  M G Dahl; M M Gregory; P J Scheuer
Journal:  Br Med J       Date:  1971-03-20
View more
  21 in total

Review 1.  Pharmacology of anticancer drugs in the elderly population.

Authors:  Hans Wildiers; Martin S Highley; Ernst A de Bruijn; Allan T van Oosterom
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 2.  Drug dosage in the elderly: dermatological drugs.

Authors:  Anna Flammiger; Howard Maibach
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

3.  Methotrexate dosage in patients aged over 50 with psoriasis.

Authors:  G M Fairris; A G Dewhurst; J E White; M J Campbell
Journal:  BMJ       Date:  1989-03-25

Review 4.  Clinical pharmacokinetics of methotrexate.

Authors:  D D Shen; D L Azarnoff
Journal:  Clin Pharmacokinet       Date:  1978 Jan-Feb       Impact factor: 6.447

Review 5.  Clinical relevance of pharmacokinetics.

Authors:  G Tognoni; C Bellantuono; M Bonati; M D'Incalci; M Gerna; R Latini; M Mandelli; M G Porro; E Riva
Journal:  Clin Pharmacokinet       Date:  1980 Mar-Apr       Impact factor: 6.447

Review 6.  Problems in the use of anticancer drugs in the elderly.

Authors:  J E Phister; S G Jue; B J Cusack
Journal:  Drugs       Date:  1989-04       Impact factor: 9.546

7.  The effects of antibiotics and uricosuric drugs on the renal elimination of methotrexate and 7-hydroxymethotrexate in rabbits.

Authors:  H Iven; H Brasch
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

Review 8.  The practical use of methotrexate in psoriasis.

Authors:  J P Tung; H I Maibach
Journal:  Drugs       Date:  1990-11       Impact factor: 9.546

9.  Concentration and pH dependent steady-state volume of distribution of methotrexate estimated by a simple physiologically based method.

Authors:  C Y Lui; M G Lee; W L Chiou
Journal:  J Pharmacokinet Biopharm       Date:  1984-12

Review 10.  Pharmacokinetics of anticancer drugs in children.

Authors:  W R Crom; A M Glynn-Barnhart; J H Rodman; M E Teresi; R E Kavanagh; M L Christensen; M V Relling; W E Evans
Journal:  Clin Pharmacokinet       Date:  1987-03       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.